Journal of Antimicrobial Chemotherapy, Vol 41, 289-291, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy
JE Stout, B Arnold and VL Yu
We evaluated a human monocyte cell line (HL-60) as a model for testing the
intracellular activity of anti-Legionella antibiotics; 1.5 x 10(6) HL-60
cells/well were differentiated into adherent cells and infected with 1.5 x
10(7) cfu of Legionella pneumophila. The most active agents against L.
pneumophila as judged by broth dilution MICs were (in order of activity)
azithromycin, clarithromycin, roxithromycin, quinupristin/dalfopristin,
erythromycin and dirithromycin. The most active inhibitors of L.
pneumophila intracellular multiplication were (in order of activity)
azithromycin, erythromycin, quinupristin/dalfopristin, roxithromycin,
dirithromycin and clarithromycin. All the agents were highly active against
Legionella micdadei and Legionella bozemanii when compared with L.
pneumophila.
ORIGINAL ARTICLES
Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells
Special Pathogens Laboratory, Veterans Affairs Medical Center, and The University of Pittsburgh School of Medicine, PA 15240, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Almahmoud, E. Kay, D. Schneider, and M. Maurin Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila J. Antimicrob. Chemother., August 1, 2009; 64(2): 284 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sabria, M. L. Pedro-Botet, J. Gomez, J. Roig, B. Vilaseca, N. Sopena, V. Banos, and for the Legionnaires Disease Therapy Group Fluoroquinolones vs Macrolides in the Treatment of Legionnaires Disease Chest, September 1, 2005; 128(3): 1401 - 1405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Roig and J. Rello Legionnaires' disease: a rational approach to therapy J. Antimicrob. Chemother., May 1, 2003; 51(5): 1119 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Jung, L. H. Danziger, and S. L. Pendland Intracellular activity of ABT-773 and other antimicrobial agents against Legionella pneumophila J. Antimicrob. Chemother., May 1, 2002; 49(5): 857 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takemura, H. Yamamoto, H. Kunishima, H. Ikejima, T. Hara, K. Kanemitsu, S. Terakubo, Y. Shoji, M. Kaku, and J. Shimada Evaluation of a human monocytic cell line THP-1 model for assay of the intracellular activities of antimicrobial agents against Legionella pneumophila J. Antimicrob. Chemother., October 1, 2000; 46(4): 589 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jonas, I. Engels, F. D. Daschner, and U. Frank The effect of azithromycin on intracellular Legionella pneumophila in the Mono Mac 6 cell line at serum concentrations attainable in vivo J. Antimicrob. Chemother., September 1, 2000; 46(3): 385 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. N. Vergis, A. Indorf, T. M. File Jr, J. Phillips, J. Bates, J. Tan, G. A. Sarosi, J. T. Grayston, J. Summersgill, and V. L. Yu Azithromycin vs Cefuroxime Plus Erythromycin for Empirical Treatment of Community-Acquired Pneumonia in Hospitalized Patients: A Prospective, Randomized, Multicenter Trial Arch Intern Med, May 8, 2000; 160(9): 1294 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dedicoat and P. Venkatesan The treatment of Legionnaires' disease J. Antimicrob. Chemother., June 1, 1999; 43(6): 747 - 752. [Full Text] [PDF]
|
|